Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
ZNF274 Blocks Lineage Switch, Fuels CDK7 Drug Resistance
Researchers published in Nature Communications that the zinc‑finger protein ZNF274 acts as a molecular gatekeeper in pancreatic cancer, limiting lineage plasticity and preserving sensitivity to CDK7 inhibitors. Loss of ZNF274 triggers enhancer reprogramming, epithelial‑to‑mesenchymal transition and transcriptional heterogeneity, enabling cells to bypass CDK7‑mediated cytostasis. The study combines ChIP‑seq, RNA‑seq and functional assays to map ZNF274’s chromatin occupancy and demonstrate its role in drug resistance. Findings suggest targeting ZNF274 pathways could enhance the efficacy of CDK7‑based therapies.
Community-Based Baby Hip Screening Successfully Reduces Late Diagnosis of Developmental Dysplasia
A nurse‑led, community‑based ultrasound program in Japan screened 349 infants for developmental dysplasia of the hip (DDH), achieving 95.6% coverage. The trial identified 8.7% of babies with suspected DDH, including many without clinical risk factors, and referred 42 infants for...
AI Systems Slash Drug Discovery Time, Yield New Cancer and Neurodegenerative Candidates
FutureHouse’s Robin and DeepMind’s Co‑Scientist AI agents have collapsed drug‑candidate timelines by up to 200‑fold, while NIH’s TRANSLATE‑AI has identified three repurposed drugs for Alzheimer’s and Parkinson’s with 98% pre‑clinical accuracy. The breakthroughs promise faster routes to clinical trials for...
China Rolls Out First National Longevity Medicine Training Program
China's health authorities, together with the China Non‑public Medical Institutions Association and the Asia‑Pacific Longevity Medicine Society, launched the country's first national, competency‑based training program in longevity medicine. The curriculum targets licensed physicians across specialties and seeks to embed preventive,...
FDA Grants First U.S. Approval for Bulevirtide, Gilead’s Hepatitis D Therapy
The FDA approved Gilead Sciences' bulevirtide‑gmod (Hepcludex) on May 22, 2026, marking the first U.S. therapy for chronic hepatitis delta virus. The drug earned accelerated approval, priority review, breakthrough therapy and orphan‑drug designations after a phase‑3 trial showed a 48%...
Novo Nordisk Cuts Drug Launch Time by Two‑Thirds Using AI, Expands India Hub
Novo Nordisk announced that artificial‑intelligence tools are trimming new‑drug launch cycles by as much as two‑thirds, with its Bengaluru, India centre now handling a majority of preparatory work for global rollouts. The move aims to recapture momentum in the fast‑growing...
AbbVie’s MAVIRET Wins Positive CHMP Opinion, 96% Cure Rate for Acute Hepatitis C
AbbVie announced that the European Medicines Agency’s CHMP has issued a positive opinion on MAVIRET for acute hepatitis C, citing a 96% cure rate in an eight‑week Phase 3 trial. The recommendation paves the way for EU approval in the third...
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
Starting July 2026, Medicare will pilot a GLP‑1 Bridge program that covers weight‑loss drugs such as Wegovy, Zepbound and Foundayo for a flat $50 monthly copayment. Eligibility hinges on a BMI of 27 or higher with a qualifying condition, or...
Healium Clinical Secures FDA Registration as Class II Biofeedback Device for Meditation Therapy
Healium announced that its VR‑enabled platform, Healium Clinical, has been registered with the U.S. FDA as a Class II 510(k)-exempt biofeedback medical device. The clearance clears a regulatory hurdle for immersive meditation‑based stress‑management tools and positions the company for broader clinical...
McKesson Posts $403B Record Revenue as AI Revamps Distribution Network
McKesson Corp. announced full‑year 2026 consolidated revenue of $403 billion, a 12% rise, while embedding artificial intelligence across its distribution, oncology and biopharma services. The AI rollout, highlighted by a new Montreal hub and a unified planning platform, helped generate $6.2 billion...
UN and AU Sign Landmark Agreement Guaranteeing Access to Safe Health Products
The World Health Organization and the African Medicines Agency have signed a five‑year Framework Agreement for Collaboration, announced at the 79th World Health Assembly. The pact aims to harmonize legal and regulatory frameworks across Africa, strengthening oversight of medical products...
Regeneron Reports Positive Phase 1/2 Data for Lynozyfic in Systemic AL Amyloidosis
Regeneron Pharmaceuticals released positive Phase 1/2 LINKER‑AL2 data for Lynozyfic in second‑line-plus systemic AL amyloidosis. The bispecific BCMAxCD3 antibody, built on VelociImmune technology, could become the first approved therapy after standard‑of‑care failure, a gap affecting thousands of patients.
Smile Train and Miss Cosmo Queens Champion Cleft Care Awareness
Smile Train teamed with Miss Cosmo pageant winners for a visit to St. Vincent General Hospital in Marikina, Philippines. The event brought international beauty queens, patients, families, and local medical partners together to spotlight cleft lip and palate awareness and...
Telangana Cabinet Clears New Life Sciences Policy 2026-30
The Telangana cabinet approved a Life Sciences Policy for 2026‑30 aimed at positioning the state among the world’s top five life‑science hubs. The plan bundles incentives for R&D units, targets 500,000 new jobs and seeks to draw roughly $25 billion in...
Scribe Therapeutics Unveils Safer CRISPR Platform Targeting Heart Disease
Scribe Therapeutics announced at the ASGCT 2026 meeting that its new ELXR CRISPR platform silences the PCSK9 gene with 10‑ to 100‑fold fewer off‑target edits and achieved an 18‑month cholesterol‑lowering effect in non‑human primates, positioning the company for first‑in‑human trials...
Lupin Gains Chinese Approval for Pediatric Flu Antiviral, Opening Its First Market in China
Lupin Limited has secured Chinese regulatory approval for its Oseltamivir Phosphate Oral Suspension, a child‑friendly flu antiviral developed with Yabao Pharmaceuticals. The clearance marks Lupin's first product launch in China, a market that could reshape its growth trajectory and influence...
Oklahoma Gov. Kevin Stitt Signs $100,000 Penalty Law Targeting Abortion Drug Distribution
Oklahoma Governor Kevin Stitt signed House Bill 1168, criminalizing the distribution of abortion pills with a felony punishable by up to $100,000 in fines and ten years in prison. The measure, championed by Republican lawmakers, draws sharp criticism from Democrats...
WHO Raises DRC Ebola Risk to "Very High" As Cases Top 800, US and Thailand Impose Travel Bans
The World Health Organization upgraded the Ebola outbreak in the Democratic Republic of Congo to its highest "very high" risk level as confirmed cases topped 800 and deaths exceeded 180. The United States and Thailand responded with new travel restrictions...
EU Approves Agios' PYRUKYND as First Disease‑Modifying Therapy for Adult Thalassemia
Agios Pharmaceuticals announced that the European Commission has granted approval for PYRUKYND (mitapivat) to treat adult patients with alpha‑ or beta‑thalassemia. The authorization covers all EU member states and marks the first disease‑modifying therapy available for both transfusion‑dependent and non‑transfusion‑dependent...
The Hidden Cost of Medical Malpractice Litigation
Medical malpractice litigation imposes hidden costs beyond direct payouts, eroding clinician confidence and prompting defensive medicine. The article highlights how complex, multimorbid cases in an aging society amplify litigation risk, leading to increased healthcare spending and workforce strain. It argues...
Off-Campus Outpatient Billing Rules Could Extend to Commercial Claims
Congress’s House Education and Workforce Committee unanimously passed the Transparency in Billing Act, extending the off‑campus outpatient department (OPD) identifier requirement from Medicare to commercial health plans. Starting with health‑plan years on Jan. 1, 2027, insurers must reject claims that omit a...
New US Dietary Guidelines Flawed, Protein Section Unsubstantiated
On the things wrong in them new US dietary guidelines (DGAs) in today's @NEJM, the "most significant reset of federal nutrition policy". Section on protein below, elsewhere gets ino beef tallow and other changes w/o evidence https://t.co/uepeVk2a38 https://t.co/q6QV9r27rP
Deep Brain Stimulation Saved My Life From Depression
What is deep brain stimulation (DBS) for depression, and what would induce someone to undergo a brain surgery like this? Hear from guest Jon Nelson how it saved his life. https://t.co/qSWninYAR8 https://t.co/BGafQaZaCf
Fragmented Care Needs Clinical Direction, Not More Data
The article argues that modern fragmented health care provides abundant data but lacks active clinical direction, leaving patients to piece together disparate specialist opinions. Without a clinician consistently integrating these perspectives, care becomes a series of isolated encounters. This disjointed...
Thermoreversible Biogel May Solve a Hairy Problem for Wearable Brain-Monitoring Systems
Penn State researchers unveiled a thermoreversible semiconducting ionic biogel that liquefies with mild heat, penetrates hair, and re‑gels on cooling to maintain scalp contact. The gel, composed of gelatin, glycerol, ionic liquids and PEDOT:PSS, achieved a thousand‑fold boost in conductivity...
The 5 Best Dental Staffing Agencies in Minneapolis for 2025
Minneapolis dental practices are losing $1,500‑$3,000 per missed hygiene day, prompting a shift toward modern staffing platforms. The article ranks seven agencies, highlighting Kwikly as the top choice because it offers real‑time matching, W‑2 employment, and full payroll and compliance...
Trump Administration Launches Moms.gov, Unveils National Pronatalist Strategy
The White House unveiled Moms.gov, a new federal website for new and expecting mothers, alongside a multi‑agency pronatalist strategy designed to reverse declining U.S. birth rates. The package includes proposals for expanded IVF coverage, financial incentives for families, and a...
Lilly's Retatrutide Cuts 30% Body Weight, New GLP‑1 Studies Target Plateaus and Joint Inflammation
Lilly’s investigational triple‑agonist retatrutide delivered an average 30.3% weight loss after 104 weeks in a Phase 3 trial, matching bariatric‑surgery outcomes. At the same time, researchers uncovered cellular mechanisms that cause GLP‑1 weight‑loss plateaus and detected GLP‑1 hormone in arthritic joint...
FDA Finds No Definitive Child Deaths Linked to COVID‑19 Vaccines After Review of 96 Cases
The Food and Drug Administration reviewed 96 vaccine‑related death reports involving children and concluded that none were definitively linked to COVID‑19 shots. The finding directly challenges former FDA vaccine chief Dr. Vinay Prasad’s claim of at least ten unreported child...
Patients Cite Health‑Plan Medication Denials as 'Unlimited' Policies Fall Short
Patients are reporting medication denials from health insurers that market 'unlimited' coverage, igniting criticism of policy wording and prompting regulators to examine claim practices. Insurers processed 32.6 million claims in the past year, with 8% rejected, while premiums surged 27% year‑on‑year.
Kathy Griffin Hospitalized After Colonoscopy Complications Highlights Screening Risks
Kathy Griffin, 65, revealed she spent a night in the hospital after complications from a routine colonoscopy. The actress‑comedian used Instagram to share the incident, drawing attention to the procedure’s role in colorectal cancer prevention and the potential for adverse...
EMA Starts Review of Regeneron's Otarmeni Gene Therapy for Genetic Hearing Loss
Regeneron Pharmaceuticals announced that the European Medicines Agency has accepted the Market Authorization Application for Otarmeni, its AAV‑based gene therapy targeting biallelic OTOF‑variant hearing loss. The acceptance moves the product into a formal EMA review, the first step toward potential...
How Lifestyle Interventions Reverse Type 2 Diabetes
Endocrinologist Mahima Gulati argues that the clinical goal for type 2 diabetes should shift from merely managing the disease to actively pursuing remission. Recent evidence shows that intensive therapeutic lifestyle change—whole‑food, plant‑predominant diets, regular activity, sleep, and stress management—can reverse metabolic...
Enhanced Ebola Airport Screening Expands to Atlanta
The U.S. Centers for Disease Control and Prevention (CDC) began enhanced Ebola entry screening at Hartsfield‑Jackson Atlanta International Airport on May 22, 2026, adding to the program already operating at Washington‑Dulles since May 20. Atlanta’s airport already had enhanced procedures, allowing a swift...
Integrating Substance Use Disorder Treatment Into Clinic-Based Internal Medicine Expands Access to Care
Researchers at the University of Cincinnati demonstrated that embedding addiction treatment within a primary‑care internal‑medicine residency clinic can broaden access to substance‑use disorder (SUD) care and markedly improve physician confidence. Over a 15‑week pilot, the clinic logged 73 patient visits,...
Northwell Health Makes Physician Well‑Being a Core Business Priority
Northwell Health has re‑engineered its clinician wellness strategy, creating a physician‑led, seven‑pillar framework that consolidates more than 100 programs into a single, measurable portfolio. The move treats burnout as a core business need, linking well‑being directly to operational and financial...
Novo Nordisk's Oral Wegovy Pill Gets EU Approval Recommendation
Novo Nordisk announced that the European Medicines Agency’s CHMP has recommended marketing authorisation for its oral Wegovy pill, a semaglutide formulation that achieved a 16.6% average weight loss in trials. The recommendation paves the way for a European launch in...
FDA Clears AstraZeneca‑Daiichi Sankyo’s Datroway for Metastatic Triple‑Negative Breast Cancer
AstraZeneca and Daiichi Sankyo announced FDA approval of Datroway for adult patients with unresectable or metastatic triple‑negative breast cancer. The decision follows a Phase 3 trial that showed a 5‑month median overall‑survival gain, positioning the drug as a Category 1 preferred first‑line...
Ebola Treatment Center Burned in Congo After Residents Blocked From Retrieving Victim’s Body
Local youths set fire to an Ebola treatment centre in Rwampara, Ituri Province, after police stopped them from retrieving a friend's body for burial. The arson highlights the clash between traditional funeral rites and strict public‑health protocols as the outbreak...
Short Naps, Long Hours: How Autism Clinics Squeeze Medicaid Dollars Out of Preschoolers
A fast‑growing chain of autism clinics in North Carolina, Compleat Kidz, enforces a seven‑minute nap limit to keep children awake for billable therapy sessions. The policy exploits Medicaid rules that only reimburse services rendered while the child is awake, allowing...
Venus Remedies Gets Saudi FDA Approval for Speciality Oncology Therapy
Venus Remedies Limited announced that the Saudi Food and Drug Authority has granted marketing authorisation for its specialty oncology drug Plerixafor, a stem‑cell mobiliser used in autologous transplants. This marks the first global approval for the therapy, positioning Saudi Arabia...
After Early Semaglutide Lead, Torrent Pharma Eyes US Liver Drug Resmetirom for India Launch
Torrent Pharmaceuticals is conducting a Phase 3 trial of Resmetirom, the first US‑approved drug for metabolic dysfunction‑associated steatohepatitis (MASH), with plans to launch in India once patent barriers lift. The company already commands a strong position in the Indian semaglutide market,...
Uganda Hosts Regional Ebola Meeting as Cross-Border Risks Rise
Health ministers from Uganda, the Democratic Republic of Congo and South Sudan convened in Kampala for a two‑day Africa CDC‑organized summit to coordinate a regional response to the Bundibugyo strain of Ebola. Uganda reports one confirmed case in isolation and...
Evaluating Mobility Plan Impact in Swiss Geriatric Clinic
A Swiss geriatric clinic conducted a quality‑improvement study, soon to appear in BMC Geriatrics, evaluating a structured mobility plan integrated into routine inpatient care. The multidisciplinary intervention combined personalized activity goals, wearable sensor monitoring, and environmental modifications, overseen by geriatricians,...
Clinical Efficacy Analysis of Single-Port Endoscopy and Unilateral Biportal Endoscopy in the Treatment of Lumbar Spinal Tuberculosis
A retrospective study of 48 lumbar spinal tuberculosis patients compared single‑hole split endoscopy (OSE) with unilateral biportal endoscopy (UBE). The OSE group (n=26) showed significantly shorter operative times, reduced blood loss, and faster early pain relief than the UBE group...
Biding Time: SCOTUS Denies Cert in Lilly, but the Constitutional Threat to FCA Relators May Only Be Getting Closer
The Supreme Court denied Eli Lilly's petition for certiorari on May 18, 2026, leaving an approximately $220 million False Claims Act judgment untouched. The case stems from a qui tam action alleging underpayment of Medicaid rebates, while a parallel constitutional challenge—whether relators are unconstitutionally...
Abridge Hires Former Slack and Notion Exec San Oo as CTO to Scale AI‑driven Clinical Platform
Abridge announced San Oo, a former senior engineering leader at Slack and Notion, as its new chief technology officer. The hire is intended to accelerate the company’s AI platform, which already serves more than 270 major U.S. health systems and...
BioVigil Names Brad Ryba CTO to Boost AI‑enabled Hand‑hygiene Platform
BioVigil announced the appointment of Brad Ryba as chief technology officer, tasking him with scaling the company’s AI‑powered hand‑hygiene platform. Ryba brings more than 25 years of technology leadership across SaaS, healthcare, and telecom, positioning BioVigil to deepen data integration...
CMU and Cleveland Clinic Launch CMR-CLIP AI, Boosting Cardiac MRI Accuracy to 99%
Carnegie Mellon University and Cleveland Clinic introduced CMR-CLIP, an AI system that outperforms generic models by more than 35% and achieves up to 99% accuracy in cardiac MRI interpretation. Trained on over 13,000 de‑identified scans, the tool aims to cut...
Pim1 Identified as Promising Therapeutic Target for Inflammatory Arthritis Treatment
Researchers have pinpointed the serine/threonine kinase Pim1 as a pivotal driver of abnormal Th17 cell differentiation in inflammatory arthritis. Elevated Pim1 levels were detected in CD4⁺ T cells from rheumatoid arthritis and ankylosing spondylitis patients, and mice lacking Pim1 in...